Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Cassava Stock Has Reached a Positive Turning Point

By Chris Lau, InvestorPlace Contributor

Cassava is rebounding and SAVA stock may rally back to its old highs as it fends off a short-selling attack.

Why Investors Think Carnival Stock Is Poised to Soar

By Chris Lau, InvestorPlace Contributor

The global increase in vaccinations will reduce the spread of Covid-19, enabling cruise companies to meet rising demand and boost CCL stock.

Beijing Battering Only Makes Alibaba Upside Potential That Much Bigger

By Chris Lau, InvestorPlace Contributor

Markets are not giving Alibaba stock a break as the Chinese government imposes strict regulations against the firm’s business areas. Analysts' targets have big upside for BABA stock.

7 Biotech Stocks Entering the Golden Boom Phase

By Chris Lau, InvestorPlace Contributor

These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.

Coinbase Stock Will Benefit From Crypto’s Volatile Climb

By Chris Lau, InvestorPlace Contributor

Hold Coinbase on expectations of cryptocurrency volatility and prices increasing, encouraging more users to join the platform.

Load More